According to the abstract, rosiglitazone works by blocking a pathway that plays a role in the development of disabling neuropathic pain. The researchers performed several experiments to analyze how rosiglitazone affects the development of abnormal pain responses and neuropathic pain — a difficult type of pain to treat because of its association with trauma, diabetes and other conditions.
The researchers induced nerve injury in the hind legs of mice and then evaluated the effects of rosiglitazone on the development of abnormal pain responses and neuropathic pain. According to the abstract, rosiglitazone reduced the development of painful responses to stimuli that are not normally painful and decreased inflammation.
The reductions in abnormal pain responses were seen with different forms of administration of the drug, including systemic injection and local injection.
Read the current issue of Anesthesia & Analgesia.
Related Articles on Anesthesia:
Avera St. Luke’s Physicians Join Avera Medical Group
Repeated Exposure to Anesthesia Drugs Could Cause Dementia
5 Updates on the Nationwide Drug Shortage
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.